Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by TD Cowen

Maze Therapeutics (NASDAQ:MAZE) was upgraded by stock analysts at TD Cowen to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

MAZE has been the subject of several other reports. Guggenheim assumed coverage on shares of Maze Therapeutics in a research report on Tuesday. They set a “buy” rating and a $19.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on Maze Therapeutics in a report on Tuesday. They set an “overweight” rating and a $30.00 price target for the company. Leerink Partners began coverage on Maze Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $28.00 price objective for the company. Finally, Leerink Partnrs raised Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Maze Therapeutics presently has an average rating of “Buy” and a consensus target price of $25.67.

Maze Therapeutics Price Performance

Maze Therapeutics stock opened at $11.70 on Tuesday. Maze Therapeutics has a twelve month low of $10.08 and a twelve month high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.